Pluristem Therapeutics, an Israeli biotech focusing on stem cells from the placenta, has announced that their proprietary treatment has reversed the condition of a terminal 7 year old girl.
The girl suffered from aplastic bone marrow, which stops bone marrow from producing stem cells that form blood. She was treated with two round of allogeneic stem cells from matched donors, but both treatments failed. Pluristem's PLX cells (short for PLacental eXpanded cells), which are harvested from placenta and expanded using a proprietary bioreactor, are universal and do not need to be matched to each specific patient like other allogeneic treatments.
The injection of PLX cells is thought to have helped by "stimulating the recovery of the hematopoietic stem cells contained in the second bone marrow transplant that she had received over two months earlier". The girl's condition improved within 10 days of the treatment and remained steady since. She was even discharged from the hospital after nearly 9 months.
Pluristem is investigating potential uses for PLX cells to treat a variety of conditions, including acute radiation syndrome (which could be helpful after a nuclear disaster like the one at the Fukushima Daiichi plant last year) and Intermittent Claudication.
Learn more about Pluristem and their novel therapies from William Prather, Sr. VP Corporate Development, at the 4th annual Stem Cells USA and Regenerative Medicine Congress this September.